Free Trial
→ Federal Reserve Reveals Disturbing New Plan To Control Your Money (From Weiss Ratings) (Ad)tc pixel
NASDAQ:PGNY

Progyny Q3 2026 Earnings Date & Estimates

Progyny logo
$27.93 +0.10 (+0.36%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$27.93 0.00 (0.00%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Progyny is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:45 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:45 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Progyny in Q3 2026

Progyny is expected to post earnings of $0.3130 per share on revenue of $340.62 million. In the same quarter a year earlier Progyny reported $0.45 per share on revenue of $313.35 million. Progyny last reported on August 6, 2026, posting $0.55 per share and beating the $0.3348 consensus estimate. Progyny has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.3130
Expected Revenue
$340.62 million
Prior-Year EPS
$0.45
Prior-Year Revenue
$313.35 million
Expected EPS Growth
-30.4%
Expected Revenue Growth
+8.7%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.55 (Beat by +$0.2152)
Last Quarter Revenue
$350.51 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Progyny Q3 2026 Earnings FAQ

Progyny (NASDAQ:PGNY) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes.

Progyny's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:45 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Progyny to post earnings of $0.3130 per share for Q3 2026.

The consensus revenue estimate for Progyny is $340.62 million for Q3 2026.

Progyny Earnings Headlines

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Progyny (PGNY) and Merck & Company (MRK)
October 9 at 2:03 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PGNY/pressreleases/5311597/analysts-opinions-are-mixed-on-these-healthcare-stocks-progyny-pgny-and-merck-company-mrk/
Why are Progyny (PGNY) shares soaring today
October 7 at 10:38 PM  |  msn.comhttps://www.msn.com/en-us/money/other/why-are-progyny-pgny-shares-soaring-today/ar-AA2dLpa5
First Look: Elon’s “Starphone”
Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.tc pixel
October 10 at 1:00 AM  |  Stansberry Research (Ad)
PGNY or CRL: Which Is the Better Value Stock Right Now?
October 7 at 12:36 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/pgny-crl-better-value-stock-144004497.html
Progyny, Inc. Selling Season Pacing to Record Level, Revealing Critical Insights on Latest Market Dynamics
October 7 at 8:28 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/07/3376447/0/en/progyny-inc-selling-season-pacing-to-record-level-revealing-critical-insights-on-latest-market-dynamics.html
Progyny (NASDAQ:PGNY) Stock Picked Up by Analysts at Wells Fargo & Company
October 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31076658
See More Progyny Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Progyny? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Progyny and other key companies, straight to your email.

About Progyny

Progyny (NASDAQ:PGNY) (NASDAQ: PGNY) is a fertility and family-building benefits company that helps employers provide reproductive health services to their employees. Its platform is designed to support individuals and families navigating fertility treatment, preservation, adoption, surrogacy and related family-building needs.

The company offers an integrated benefits solution that combines personalized care navigation with access to a network of fertility specialists and treatment providers. Progyny also provides pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States. The company was founded in 2016 and became a publicly traded company in 2019. Its leadership includes Peter Anevski, who serves as chief executive officer.

View Progyny Profile
Earnings Tools